TuHURA Biosciences, Inc. (HURA)

TuHURA Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Selling, General & Admin	4.31	4.14	2.01
Research & Development	13.34	9.4	7.93
Operating Expenses	17.65	13.55	9.93
Operating Income	-17.65	-13.55	-9.93
Interest Expense	-4.14	-0.02	-
Interest & Investment Income	0.36	0.09	0.06
Other Non Operating Income (Expenses)	-0.26	0.04	0.21
EBT Excluding Unusual Items	-21.68	-13.43	-9.66
Other Unusual Items	-	0.33	0.29
Pretax Income	-21.68	-29.32	-9.37
Net Income	-21.68	-29.32	-9.37
Preferred Dividends & Other Adjustments	0.97	-	-
Net Income to Common	-22.65	-29.32	-9.37
Shares Outstanding (Basic)	19	12	-
Shares Outstanding (Diluted)	19	12	-
Shares Change (YoY)	56.97%	-	-
EPS (Basic)	-1.21	-2.47	-
EPS (Diluted)	-1.21	-2.47	-
Free Cash Flow	-14.79	-13.25	-7.54
Free Cash Flow Per Share	-0.79	-1.11	-
EBITDA	-17.53	-13.37	-9.56
D&A For EBITDA	0.12	0.18	0.37
EBIT	-17.65	-13.55	-9.93

Updated Feb 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q